Exhibit 4.6


 


DESCRIPTION OF REGISTRANT’S SECURITIES


REGISTERED PURSUANT TO SECTION 12 OF
THE


SECURITIES EXCHANGE ACT OF 1934


 


The following description of the securities
of Vickers Vantage Corp. I (the “Company”, “we”, “our” or similar terms) is based upon the
Company’s amended and restated memorandum and articles of association (“M&A”), the Companies Law, 2020 of
the Cayman Islands (“Companies Act”) and other applicable provisions of Cayman Islands law. We have summarized certain
portions of the M&A below. The summary is not complete and is subject to, and is qualified in its entirety by express reference
to, the provisions of our M&A, which is filed as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.6 is
a part.


 


Authorized Capital


 


Pursuant to M&A, our authorized capital
consists of 200,000,000 ordinary shares, par value $0.0001, and 1,000,000 preference shares, par value $0.0001.


 


Units


 


Composition. Each unit consists
of one ordinary share, and one-half of one redeemable warrant. Each whole warrant entitles the holder to purchase one ordinary
share for an initial exercise price of $11.50 per share, for a period of five years beginning upon consummation of an initial business
combination.


 


Listing. The Company’s
units are listed on the Nasdaq Capital Market under the ticker symbol “VCKAU.”


 


Ordinary Shares


 


Authorization. The outstanding
ordinary shares are duly authorized, validly issued, fully paid and nonassessable.


 


Listing. The Company’s
ordinary shares are listed on the Nasdaq Capital Market under the ticker symbol “VCKA.”


 


Voting Rights. Ordinary shareholders
of record are entitled to one vote for each share held on all matters to be voted on by shareholders.


 


Conversion Rights. Holders of ordinary
shares issued in the Company’s initial public offering (which we refer to as “public shares”) have the right
to demand that the Company convert such shares into a pro rata portion of the Company’s trust account upon the consummation
of our initial business combination, either in connection with a shareholder meeting called to approve the business combination
or by means of a tender offer.


 


The decision as to whether we will seek
shareholder approval of a proposed business combination or conduct a tender offer will be made by us, solely in our discretion,
and will be based on a variety of factors such as the timing of the transaction and whether the terms of the transaction would
require us to seek shareholder approval under the law or stock exchange listing requirement. We intend to conduct redemptions without
a shareholder vote pursuant to the tender offer rules of the Securities and Exchange Commission (“SEC”) unless shareholder
approval is required by law or stock exchange listing requirement or we choose to seek shareholder approval for business or other
legal reasons.


 


If a shareholder vote is not required and
we do not decide to hold a shareholder vote for business or other legal reasons, we will, pursuant to our M&A, conduct the
redemptions pursuant to the tender offer rules of the SEC, and file tender offer documents with the SEC prior to consummating our
initial business combination. Our M&A requires these tender offer documents to contain substantially the same financial and
other information about the initial business combination and the redemption rights as is required under the SEC’s proxy rules.
If, however, shareholder approval of the transaction is required by law or Nasdaq rules, or we decide to obtain shareholder approval
for business or other reasons, we will offer to redeem shares in conjunction with a proxy solicitation pursuant to the proxy rules
and not pursuant to the tender offer rules. If we seek shareholder approval, we will consummate our initial business combination
only if a majority of the outstanding ordinary voted are voted in favor of the business combination. Further, if we seek shareholder
approval, we will require public shareholders, whether they are a record holder or hold their shares in “street name,”
to either tender their certificates to our transfer agent or to deliver their shares to the transfer agent electronically using
Depository Trust Company’s DWAC (Deposit/Withdrawal At Custodian) System, at the holder’s option, in each case prior
to a date set forth in the proxy materials sent in connection with the proposal to approve the business combination. There
is a nominal cost associated with the above-referenced delivery process and the act of certificating the shares or delivering
them through the DWAC System. The transfer agent will typically charge the tendering broker a nominal amount and it would be up
to the broker whether or not to pass this cost on to the holder. However, this fee would be incurred regardless of whether or not
we require holders seeking to exercise redemption rights to deliver their shares prior to a specified date. The need to deliver
shares is a requirement of exercising conversion rights regardless of the timing of when such delivery must be effectuated. However,
in the event we require shareholders seeking to exercise redemption rights to deliver their shares prior to the consummation of
the proposed business combination and the proposed business combination is not consummated this may result in an increased cost
to shareholders.


 






    


     


    

 


Outside Date. Pursuant to our
M&A, if we are unable to consummate a business combination on or before January 6, 2022 (unless such time period is extended
by our shareholders, as provided in the M&A), we will (i) cease all operations except for the purpose of winding up, (ii) as
promptly as reasonably possible but not more than five business days thereafter, redeem 100% of the outstanding public shares which
redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive further
liquidation distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption,
subject to the approval of our remaining holders of ordinary shares and our board of directors, proceed to commence a voluntary
liquidation and thereby a formal dissolution of the company, subject (in the case of (ii) and (iii) above) to our obligations to
provide for claims of creditors and the requirements of applicable law.


 


Our initial shareholders, which include
our sponsors, officers, and directors, have entered into agreements with us, pursuant to which they have waived their rights to
liquidating distributions from the trust account with respect to their initial shares if we fail to complete our initial business
combination by January 6, 2022 (subject to extension). However, if our initial shareholders or management team acquire public shares,
they will be entitled to liquidating distributions from the trust account with respect to such public shares if we fail to complete
our initial business combination by such date.


 


Transfer Restrictions. Subject
to certain limited exceptions, our initial shareholders have agreed not to transfer, assign or sell their founder shares until
six months after the date of the consummation of our initial business combination or earlier if, subsequent to our initial business
combination, we consummate a subsequent liquidation, merger, stock exchange or other similar transaction which results in all of
our shareholders having the right to exchange their ordinary shares for cash, securities or other property.


 


Additionally, the holders of ordinary shares
purchased prior to our initial public offering have agreed (A) to vote any shares owned by them in favor of any proposed business
combination, (B) not to redeem any shares in connection with a shareholder
vote to approve a proposed initial business combination or any amendment to our M&A prior to the consummation of our initial
business combination and (C) not to sell any shares to us in a
tender offer in connection with any proposed business combination.


 


Preemptive Rights, Etc. Our
shareholders have no conversion, preemptive or other subscription rights and there are no sinking fund or redemption provisions
applicable to the ordinary shares, except that public shareholders have the right to sell their shares to us in a tender offer
or have their ordinary shares redeemed for cash equal to their pro rata share of the trust account if they vote on the proposed
business combination in connection with such business combination and the business combination is completed. Public shareholders
who sell or redeem their shares for their share of the trust account still have the right to exercise the warrants that they received
as part of the units.


 


Preference Shares


 


Our M&A provides that preference shares
may be issued from time to time in one or more series. Our board of directors is authorized to fix the voting rights, if any, designations,
powers, preferences, the relative, participating, optional or other special rights and any qualifications, limitations and restrictions,
applicable to the shares of each series. Our board of directors will be able, without shareholder approval, to issue preference
shares with voting and other rights that could adversely affect the voting power and other rights of the holders of ordinary shares
and could have anti-takeover effects. However, the underwriting agreement that we entered into in connection with the initial public
offering prohibits us, prior to a business combination, from issuing preference shares which participate in any manner in the proceeds
of the trust account, or which vote as a class with the ordinary shares on a business combination.


 


Warrants


 


Exercisability. Each whole
warrant is exercisable to purchase one ordinary share.


 


Exercise Price. $11.50 per
share, subject to adjustment.


 


The exercise price and number of ordinary
shares issuable on exercise of the warrants may be adjusted in certain circumstances including in the event of a share dividend,
extraordinary dividend or our recapitalization, reorganization, merger or consolidation. However, the warrants will not be adjusted
for issuances of ordinary shares at a price below their respective exercise prices.


 


Exercise Period. The warrants will
become exercisable on the later of January 6, 2022 or the consummation of our initial business combination. The warrants will expire
five years after the consummation of our initial business combination, at 5:00 p.m., New York time, or earlier upon our failure
to consummate a business combination on or before January 6, 2022 (subject to extension) or redemption of our ordinary shares or
our liquidation.


 


No warrants will be exercisable
for cash unless we have an effective and current registration statement covering the issuance of the ordinary shares issuable upon
exercise of the warrants and a current prospectus relating to such ordinary shares. Notwithstanding the foregoing, if a registration
statement covering the issuance of the ordinary shares issuable upon exercise of the public warrants is not effective within 90
days from the closing of our initial business combination, warrant holders may, until such time as there is an effective registration
statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on
a cashless basis pursuant to an available exemption from registration under the Securities Act. If an exemption from registration
is not available, holders will not be able to exercise their warrants on a cashless basis. The warrants will expire five years
from the closing of our initial business combination at 5:00 p.m., New York City time or earlier redemption.


 


We have agreed to use our best efforts
to file and have an effective registration statement covering the ordinary shares issuable upon exercise of the warrants, to maintain
a current prospectus relating to those ordinary shares until the earlier of the date the warrants expire or are redeemed and the
date on which all of the warrants have been exercised, and to qualify the resale of such shares under state blue sky laws, to the
extent an exemption is not available.


 






    


     


    

 


Redemption of Warrants. Once the
warrants become exercisable, we may call the warrants for redemption (excluding the private warrants and any warrants issued to
our initial shareholders, officers or directors in payment of working capital loans made to us), in whole and not in part, at a
price of $0.01 per warrant, upon not less than 30 days’ prior written notice of redemption (the “30-day redemption
period”) to each warrant holder, and if, and only if, the reported last sale price of our ordinary shares equals or exceeds
$18.00 per share (as adjusted for share splits, share dividends, reorganizations and recapitalizations), for any 20 trading days
within a 30 trading day period ending on the third business day prior to the notice of redemption to warrant holders. We will not
redeem the warrants unless an effective registration statement covering the ordinary shares issuable upon exercise of the warrants
is current and available throughout the 30-day redemption period.


 


If we call the warrants for redemption
as described above, our management will have the option to require all holders that wish to exercise warrants to do so on a “cashless
basis.” In such event, each holder would pay the exercise price by surrendering the warrants for that number of ordinary
shares equal to the quotient obtained by dividing (x) the product of the number of ordinary shares underlying the warrants, multiplied
by the difference between the exercise price of the warrants and the fair market value by (y) the fair market value. The “fair
market value” for this purpose shall mean the average reported last sale price of the ordinary shares for the 10 trading
days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. For
example, if a holder held 150 warrants to purchase 150 shares and the fair market value on the trading date prior to exercise
was $15.00, that holder would receive 35 shares without the payment of any additional cash consideration. Whether we will
exercise our option to require all holders to exercise their warrants on a “cashless basis” will depend on a variety
of factors including the price of our ordinary shares at the time the warrants are called for redemption, our cash needs at such
time and concerns regarding dilutive share issuances.


 


Fractional Shares. No fractional
shares will be issued upon exercise of the warrants. If, upon exercise of the warrants, a holder would be entitled to receive a
fractional interest in a share, we will, upon exercise, round up to the nearest whole number the number of ordinary shares to be
issued to the warrant holder.


 


Listing. The Company’s
warrants are listed on the Nasdaq Capital Market under the ticker symbol “VCKAW.”


 


Certain Provisions
of our M&A 


 


Our amended and restated
memorandum and articles of association filed under the laws of the Cayman Islands contain provisions designed to provide certain
rights and protections to our shareholders prior to the consummation of a business combination. The following are the material
rights and protections contained in our amended and restated memorandum and articles of association:


 


•        the
right of public shareholders to exercise redemption rights and have their public shares repurchased in lieu of participating in
a proposed business combination (up to a maximum of 20% of the public shares sold in this offering);


 


•        a
prohibition against completing a business combination unless we have net tangible assets of at least $5,000,001 immediately prior
to or upon consummation of such business combination;


 


•        a
requirement that if we seek shareholder approval of any business combination, a majority of the issued and outstanding ordinary
shares voted must be voted in favor of such business combination;


 


•        the
separation of our board of directors into three classes and the establishment of related procedures regarding the standing and
appointment of such directors;


 


•        a
requirement that directors may call general meetings on their own accord and are required to call an extraordinary general meeting
if holders of not less than 10% in par value of the issued shares request such a general meeting;


 


•        a
requirement that our management take all actions necessary to liquidate our trust account in the event we do not consummate a business
combination by 12 months from the consummation of this offering (or up to 18 months if we extend the time to consummate
a business combination as described herein;


 


•        a
prohibition, prior to a business combination, against our issuing (i) any ordinary shares or any securities convertible into ordinary
shares or (ii) any other securities (including preference shares) which participate in or are otherwise entitled in any manner
to any of the proceeds in the trust account or which vote as a class with the ordinary shares on a business combination; and


 


•        the
limitation on shareholders’ rights to receive a portion of the trust account.


 


The Companies Law permits a company incorporated
in the Cayman Islands to amend its memorandum and articles of association with the approval of the holders of at least two-thirds of
such company’s issued and outstanding ordinary shares. A company’s articles of association may specify that the approval
of a higher majority is required but, provided the approval of the required majority is obtained, any Cayman Islands company may
amend its memorandum and articles of association regardless of whether its memorandum and articles of association provides otherwise.
Accordingly, although we could amend any of the provisions relating to our proposed offering, structure and business plan which
are contained in our amended and restated memorandum and articles of association, we view all of these provisions as binding obligations
to our shareholders and neither we, nor our officers or directors, will take any action to amend or waive any of these provisions
unless we provide public shareholders with the opportunity to convert their public shares in connection with any such vote. The
foregoing is set forth in our amended and restated memorandum and articles of association and cannot be amended.